What is the new treatment for dry eyes?

The newest treatments for dry eyes include MIEBO, VEVYE, TYRVAYA, XDEMVY, and in-office procedures like IPL therapy and thermal gland treatments. These innovative options target different causes of dry eye disease in Phoenix patients. Dry eyes affect millions of Americans, causing burning, itching, and blurry vision.

Arizona’s Vision Eye Care Center has tracked these breakthrough treatments since their development. Our 20+ years of experience helps us match the right solution to your specific dry eye type.

You’ll discover which new treatments might work best for your symptoms. This article explains the latest options, how they work, and why traditional drops often fail.

New In-Office Procedures for Dry Eye Treatment in Phoenix, AZ

In-office dry eye treatments provide lasting relief beyond what drops can offer. These procedures target the root causes of dry eye disease. Patients often see improvements after just one session.

Intense Pulsed Light (IPL) therapy

IPL therapy melts blockages in oil glands and reduces eye inflammation. This treatment uses gentle light pulses on the skin near your eyes. The light energy improves oil gland function and stabilizes your tear film.

Radiofrequency (RF) therapy

RF therapy uses controlled heat to unclog meibomian glands effectively. The gentle warming helps restore proper oil flow to your tears. Patients report improved comfort and fewer dry eye symptoms after treatment.

BlephEx

BlephEx cleans eyelids by removing bacterial biofilm and debris. This quick procedure uses a spinning tool with medical-grade cleaner. The treatment prevents inflammation and improves tear production.

iLux²

iLux² delivers targeted heat and pressure to clear blocked oil glands. The handheld device treats both upper and lower eyelids. Patients experience improved tear quality and reduced dry eye symptoms.

New and Emerging Dry Eye Treatments (2023–2025)

Recent years have brought remarkable innovations for dry eye sufferers. These new medications target specific causes rather than just symptoms. Each treatment works differently based on your dry eye type.

MIEBO (perfluorohexyloctane)

MIEBO treats evaporative dry eye by forming a protective layer on the eye surface. This FDA-approved eye drop specifically targets tear evaporation. It helps patients with meibomian gland dysfunction who have poor oil quality.

VEVYE (cyclosporine 0.1%)

VEVYE reduces inflammation and boosts natural tear production effectively. This water-free formula stays on the eye longer than older versions. Patients with inflammatory dry eye see improvements within weeks.

TYRVAYA (varenicline)

TYRVAYA stimulates tear production through a unique nasal spray delivery. This medication activates natural tear production pathways. Many patients notice increased moisture within minutes after use.

Tryptyr (acoltremon ophthalmic solution)

Tryptyr activates corneal nerves to increase natural tear production. This 2025-approved treatment helps patients with aqueous tear deficiency. The drops work by stimulating special receptors in your eye.

EYSUVIS (loteprednol 0.25%)

EYSUVIS treats dry eye flares with short-term steroid therapy. This targeted approach reduces inflammation quickly. Patients use it for brief periods when symptoms worsen.

XDEMVY (lotilaner 0.25%)

XDEMVY treats Demodex blepharitis, a common cause of dry eyes. This medication kills microscopic mites that block oil glands. Patients with eyelid redness and crusty debris benefit most.

LACRIFILL Hyaluronic-Acid Canalicular Gel

LACRIFILL blocks tear drainage to keep natural tears on your eyes longer. This gel creates a temporary plug in tear ducts. The treatment helps patients whose tears drain too quickly.

Treatments in Development for Dry Eye Disease

Several promising treatments are moving through clinical trials now. These therapies target new pathways for dry eye relief. Patients may have access to these options soon.

Reproxalap (Aldeyra)

Reproxalap targets inflammatory molecules that cause dry eye symptoms. This medication is currently under FDA review. Clinical trials show promising results for inflammatory dry eye.

Immunoglobulin eye drops (Selagine)

Immunoglobulin eye drops entered Phase II clinical trials in 2025. These drops may help regulate immune response in dry eyes. The treatment shows promise for severe inflammatory cases.

PL9643 (Palatin Technologies)

PL9643 is in Phase III trials with results expected by late 2025. This therapy targets inflammation through a new mechanism. Early studies show good safety and effectiveness.

Why Dry Eye Is So Difficult to Treat

Dry eye disease has multiple causes that often overlap. Standard drops only address symptoms temporarily. The condition involves complex interactions between tears, oil glands, and inflammation.

Most patients need treatments that target their specific type of dry eye. One-size-fits-all approaches typically fail to provide lasting relief. Proper diagnosis is essential for effective treatment.

Conclusion

The newest dry eye treatments offer hope beyond traditional artificial tears. These innovative options target specific causes like oil gland dysfunction, inflammation, and mite infestations. Each treatment works differently based on your unique dry eye type.

Arizona’s Vision Eye Care Center provides comprehensive dry eye evaluations in Phoenix. We match patients with the most effective new treatments for their specific condition. Our experts stay current with the latest advances in dry eye care.

Contact us today to discover which new dry eye treatment might work best for you. We’ll help you find lasting relief with personalized care that addresses the root cause of your symptoms.